mmq
ATL1102 is being designed as a platform for multiple indications where inflammation control is crucial - using the CD49d thesis.
Wayne / George have made some great commentary here about the 'platform' approach and why it's so valued by Pharma.
What ANP shareholders will relize shortly is the latent value of that initial MS trial using ATL1102 - that data is gold.
Between the MS trial dose of +200mg and DMD trial dose of 25mg - ANP has data to formulate a plan for new indications based on REAL clinical data. Not just lab rat modelling.
Considering what some 'pre-clinical' IP is selling for in the USA - we are in a great position with 2 x Phase 2 successful trials.
.
Chart, page-2947
-
- There are more pages in this discussion • 2,959 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
